Benzinga · Oct 1, 2026
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25
Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $24 to $25.
NASDAQ · ATOS
Atossa Therapeutics, Inc.
Healthcare · Biotechnology
$2.39
Up+$0.17 (+7.17%)
Updated Oct 13, 2026, 11:00 PM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 116.87M
- P/E ratio
- -4.07
- Dividend yield
- 0.00%
- 52-week range
- $1.70 – $19.35
- Volume
- 81.42K
- Avg. volume
- 872.57K
Price performance · ATOS
ATOS price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 12, 2026
ATOS closed at $2.39 after 21 trading sessions, down 3.68% for the selected period.
- Last close
- $2.39
- Period change
- -3.68%
- Period low
- $1.90
- Period high
- $2.48
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 12, 2026 | $2.44 | $2.53 | $2.335 | $2.3887 | 81.42K |
| Oct 9, 2026 | $2.45 | $2.74 | $2.12 | $2.44 | 265.61K |
| Oct 8, 2026 | $2.46 | $2.478 | $2.385 | $2.42 | 101.01K |
| Oct 7, 2026 | $2.41 | $2.49 | $2.41 | $2.46 | 19.07K |
| Oct 6, 2026 | $2.46 | $2.54 | $2.43 | $2.45 | 54.63K |
| Oct 5, 2026 | $2.38 | $2.4999 | $2.341 | $2.45 | 53.32K |
| Oct 2, 2026 | $2.23 | $2.3791 | $2.17 | $2.34 | 74.27K |
| Oct 1, 2026 | $1.96 | $2.30 | $1.96 | $2.27 | 113.6K |
| Sep 30, 2026 | $1.99 | $2.15 | $1.95 | $1.95 | 67.77K |
| Sep 29, 2026 | $2.06 | $2.16 | $1.96 | $1.99 | 83.32K |
| Sep 28, 2026 | $1.905 | $2.04 | $1.82 | $1.96 | 152.93K |
| Sep 25, 2026 | $2.06 | $2.0652 | $1.89 | $1.90 | 77.84K |
| Sep 24, 2026 | $2.15 | $2.22 | $2.05 | $2.05 | 37.46K |
| Sep 23, 2026 | $2.25 | $2.26 | $2.15 | $2.18 | 37.19K |
| Sep 22, 2026 | $2.25 | $2.43 | $2.25 | $2.26 | 129.53K |
| Sep 21, 2026 | $2.25 | $2.39 | $2.25 | $2.25 | 67.17K |
| Sep 18, 2026 | $2.37 | $2.38 | $2.22 | $2.22 | 39.76K |
| Sep 17, 2026 | $2.42 | $2.43 | $2.37 | $2.40 | 33.29K |
| Sep 16, 2026 | $2.39 | $2.48 | $2.39 | $2.42 | 45.78K |
| Sep 15, 2026 | $2.475 | $2.49 | $2.37 | $2.37 | 43.78K |
| Sep 14, 2026 | $2.53 | $2.555 | $2.45 | $2.48 | 35.04K |
Latest ATOS news
The latest Smart Investors Daily articles mentioning ATOS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ATOS research
Overview
Company profile and research snapshot.
Company profile
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $5.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 1, 2026 | Ascendiant Capital | Buy | — |
| Jul 7, 2026 | Rodman & Renshaw | Buy | — |
| Apr 10, 2026 | Ascendiant Capital | Buy | — |
| Mar 26, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 8, 2025 | Ascendiant Capital | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 30, 2026
Atossa plans shareholder stake in potential PRV proceeds
Shareholders could be set for a cash reward if the biotech wins a voucher upon approval of (Z)-endoxifen.
Yahoo · Sep 29, 2026
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, today announced that its Board of Directors has approved a plan to issue one contingent value right ("CVR") for each share of Atossa common stock to enable shareholders to share in a portion of any proceeds received from the monetization of Atossa's first qualifying rare pediatric disease priority r
Yahoo · Sep 24, 2026
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Steven Quay, M.D., Ph.D., Atossa's President and Chief Executive Officer, will participate as a panelist at the 13th Aging Research and Drug Discovery Meeting (ARDD 2026), being held October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University in Boston, MA.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
